Terry J. Rosen - 23 Jan 2024 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Executive Officer, Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
23 Jan 2024
Transactions value $
$0
Form type
4
Filing time
25 Jan 2024, 19:39:26
Previous filing
02 Jan 2024
Next filing
31 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Award $0 +100K +2.59% $0.00 3.97M 23 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (right to buy) Award $0 +406K $0.00 406K 23 Jan 2024 Common Stock 406K $15.44 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company.
F2 The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.